Albuminuria: a target for clinical trials in kidney disease?

Albuminuria: a target for clinical trials in kidney disease?Albuminuria: a target for clinical trials in kidney disease?, Published online: 14 February 2019; doi:10.1038/s41581-019-0123-xA reduction in proteinuria and albuminuria has long been proposed as a surrogate biomarker for clinically validated end points for interventional trials in patients with kidney disease. Taken together, the findings of two recent landmark meta-analyses present a formidable argument favouring such surrogacy but some uncertainty remains.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research